News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Erectile Function Vs Erectile Dysfunction: How MangoRx’s (NASDAQ: MGRX) Product Sets Itself Apart and Caters to a Large Market (Pun Intended)

Benzinga

By Meg Flippin, Benzinga Ever since the pandemic, telemedicine has been taking off, and for good reason. It's easy, convenient and increases access for people around the globe. It can also be game-changing for men dealing with what they may consider embarrassing medical conditions like erectile dysfunction. After all, being seen online by a physician enables them to avoid any in-person awkward conversations. Not to mention it can be a lot cheaper and more accessible. And let's not forget the countless men who may not have a problem getting an erection but who want to enhance their performance and enjoy a prolonged and enhanced experience with their partner. They, too, can benefit from such products but often don’t obtain a prescription because they are embarrassed – such products are no longer only for erectile dysfunction but also for improved erectile function. Despite the benefits, it's only recently that men-focused healthcare companies have begun popping up online. They are changing the landscape, making it easy for men to seek help for conditions that aren’t life-threatening but can be life-altering, like ED or to simply keep it up for longer. Mangoceuticals, Inc. (NASDAQ: MGRX), which goes by MangoRx, is among them. It is taking the shame out of getting help and getting hard with its telemedicine platform and ED drugs, and is committed to a more accepting and educational approach to men’s health. Patients don’t have to come into an office to get a prescription. Everything is done online and in minutes. Fast delivery means customers are up and performing in no time. No Shame With MangoRx MangoRx is changing the narrative on ED with its fun and humorous brand voice meant to encourage and empower men to get the help they need. MangoRx uses cheeky humor and quite frankly straightforward language to market towards millions of men to, as they put it, simply have better sex. Taking the shame and awkwardness about common problem, the company is focused on developing, marketing and selling a variety of men’s health and wellness products in the area of ED, hair growth, weight loss and hormone replacement therapies. It leverages a telemedicine platform to discreetly treat its growing base of patients–it's a big market opportunity for MangoRx, especially for the treatment of ED. ED is a widespread and global problem that is rapidly growing, even among young adults. By the end of 2025 there are forecast to be about 322 million cases of ED. As a result, the market for ED drugs and treatments is projected to grow from $3 billion today to over $7 billion by 2032, representing a CAGR of 9% during the forecast period. Many cases of this treatable condition go undiagnosed, however, because of embarrassment. MangoRx’s opportunity isn’t only limited to men suffering from ED. The company’s product can also be used as a performance enhancer. With billions of men sexually active around the globe, the performance enhancement market is also a big one for the company. Drugs like Cialis and Viagra are household names, but there are others on the market that claim to offer benefits over the incumbent. MangoRx says it’s in that category. Its ED pill, Mango, is fast-acting, and the company says very effective. Mango hits the bloodstream in as little as ten minutes and lasts for up to four hours. That gives it a leg up over Viagra, which takes up to 60 minutes to work, and Cialis, which takes about 30 minutes. Treatments start at $12.50 a tablet, making it an affordable option compared to some of its rivals which include Hims & Hers (NYSE: HIMS), Maximus Tribe and Nu Image. Whether you are using it to perform or to enhance the experience, there is no pre-gaming or wining and dining with Mango. Ten minutes after taking the pill, you are ready to go for hours to come. Viagra And Cialis With A Twist Mango is created using a formula of the same active ingredients in Cialis (Tadalafil) and Viagra (Sildenafil). But instead of using just either of the two substances that have been proven to increase blood flow to the penis alone, Mango adds Oxytocin, the so-called love hormone that helps stimulate feelings of intimacy and L-Arginine, an amino acid that opens blood vessels and helps increase blood flow, to the mix. All four of the substances are FDA-approved and have been on the market for years. The result: a fast-acting pill that lasts for hours. Spontaneity is in with Mango. Developing a fast-acting ED pill that’s wallet-sized and tastes good is an achievement in itself, but MangoRx makes it easy to obtain the drugs, which is another game changer. Mango requires a prescription, but obtaining it is easy on MangoRx’s telemedicine platform. After completing an online telehealth visit, one of its network of medical providers will review and approve a prescription. MangoRx will ship it in a discreet box to maintain privacy. It's as simple as that, which appeals to its growing customer base. Sales in MangoRx’s first quarter rose 108%. Whether men need help with ED or want to enhance their sexual experiences, MangoRx makes it easy. The telemedicine platform is quick, easy and discreet. The pills are fast-acting, effective and affordable. With all that to offer, MangoRx seems to be on the way up – like its growing base of clients. Featured photo by Becca Tapert on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

July 10, 2024 09:15 AM Eastern Daylight Time

Image
Article thumbnail News Release

Functional Medicine Network Strengthens Leadership with Appointment of Visionary Chief Financial Officer

Forum Health

Forum Health, LLC, the first nationwide network of integrative and functional medicine providers, is pleased to announce the appointment of Sean Whelan as its new chief financial officer. With a distinguished career spanning over three decades, including nearly two decades in healthcare services, Sean brings a proven track record and results-driven leadership to Forum Health. Learn more about Forum Health. Phil Hagerman, Forum Health CEO: "Mr. Whelan is an experienced financial executive with expertise in driving growth and leading transformation. His deep understanding of healthcare economics and commitment to financial stewardship will undoubtedly pilot Forum Health to the next phase of profitable growth.” As CFO, Whelan will lead strategic financial initiatives to enhance operational efficiency, mitigate risks, and foster expansion in a dynamic healthcare environment. Additionally, he will implement robust financial planning, foster stakeholder relationships, and guide investments in innovation and compliance, to ensure Forum Health remains competitive and resilient while delivering superior patient care. Sean Whelan, Forum Health CFO: "I am honored to join such a talented, forward-thinking leadership team at Forum Health that is at the forefront of redefining healthcare. Together, we will continue to push the boundaries of what is possible and deliver exceptional outcomes for our patients, clinics and many stakeholders." Whelan's accomplished background includes CFO roles at InfuSystem Holdings (NYSE MKT: INFU), Diplomat Pharmacy (NYSE: DPLO), and Smile America Partners, and both CEO and CFO roles at Encore Rehabilitation Services. At Diplomat, he led the company’s successful 2014 Initial Public Offering, and helped grow the business from $200 million to $4.5 billion during his tenure. He has held key leadership roles in closely held, private equity backed, and public companies. Sean also presently serves on the Board of Directors of Zomedica (NYSE MKT: ZOM) and the University of Michigan’s Ross School of Business Alumni Board of Governors. For more information about Forum Health and its services, please visit www.forumhealth.com. About Forum Health, LLC Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. Contact Details Forum Health Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

July 10, 2024 08:50 AM Eastern Daylight Time

Image
Article thumbnail News Release

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Benzinga

By Anthony Termini, Benzinga In 2023, television personality Maria Menounos acknowledged that she had been diagnosed with pancreatic cancer. Fortunately for Menounos, physicians detected the rare, less aggressive form of the disease when it was still in an early stage. Pancreatic cancer is one of the least survivable forms of the disease. According to the National Institutes of Health (NIH), pancreatic cancer is currently the third leading cause of cancer-related deaths in America. Furthermore, Menounos’s case is part of a disturbing trend. Incidents of pancreatic cancer are increasing, with the number of cases in women under the age of 55 rising at a disproportionate rate compared to men. Pancreatic Cancer Is Difficult To Find And Painful To Treat When it is in the early stages, pancreatic cancer usually offers no clearly-identifiable symptoms. The types of screens suggested for breast cancer or colon cancer don’t exist for pancreatic cancer, and there is no single diagnostic test to detect it. According to Johns Hopkins University, a clear diagnosis typically emerges only after an extensive series of imaging scans, blood tests and biopsies. Since these tests are generally conducted only after symptoms are felt, an initial diagnosis often reveals that the cancer is in an advanced stage that has spread to other organs. As a result, most patients tend to get a relatively aggressive form of chemotherapy. The combination of drugs used can often result in severe side effects. However, that may change as a result of work being conducted in current clinical trials. A Novel Approach To Treat Pancreatic Cancer Holds Promise Rockville, Maryland-based Theriva Biologics (AMEX: TOVX) is currently in a phase 2b trial with patients diagnosed with metastatic pancreatic ductal adenocarcinoma (PDAC). Theriva is a leader in the development of oncolytic virus therapies – treating cancer with viruses that target tumors. Theriva’s lead therapy candidate is VCN-01, a highly differentiated oncolytic adenovirus that replicates and destroys cancer tissue. The trial is studying the use of VCN-01 in combination with two forms of chemotherapy drugs. Oncolytic virus therapies target specific genes or proteins involved in the disease process to block or alter their activity and ultimately halt or reverse disease progression. The goal is to help patients live longer with less severe side effects. Theriva’s trial results so far appear promising. “We believe VCN-01’s differentiated mechanism of action has the potential to address the urgent need for new treatment options for patients with PDAC by degrading the tumor matrix and increasing tumor access,” said Steven Shallcross, Theriva’s CEO. The company’s current clinical trial is studying a combination of VCN-01 with a drug that mimics some of the building blocks of RNA and DNA to disrupt a cancer cell’s ability to make proteins (Gemcitabine) and one that includes a human protein to stop cancer cells from dividing and multiplying (nab-Paclitaxel). The NIH notes that gemcitabine has been the standard first-line treatment for advanced pancreatic cancer for 15 years and is often used in combination with nab-paclitaxel as first-line treatment for pancreatic cancer. Theriva’s Shallcross noted that repeated systemic dosing of VCN-01 with this standard-of-care chemotherapy is feasible from a safety perspective. “We have shown that the combination has an acceptable safety profile, and can now focus on whether the repeated-dose VCN-01 regimen may lead to improved clinical outcomes for patients with PDAC and other solid cancers,” he said. Studying Pancreatic Cancer Offers Challenges, And The Need Is Large According to gastrointestinal oncologist Mridula Krishnan, MBBS, “Pancreatic cancer is not an easy cancer to study and, especially when it comes to gender-related studies, it’s very tough to find answers.” This is part of what makes Theriva’s work so important. The company believes that its oncolytic viruses are particularly well-positioned for use with other therapies to help pancreatic cancer patients achieve improved outcomes with fewer negative side effects. Mr. Shallcross noted that there is a “high unmet need” and that the company is continuing “to build a portfolio of potentially improved therapeutic combinations for PDAC patients.” According to DataBridge Market Research, that high unmet need is estimated to reach more than $6.2 billion by 2029. Theriva Biologics is also exploring the potential of VCN-01 as a possible candidate as part of other chemotherapy combinations to treat pediatric refractory retinoblastoma and adult ovarian cancer. Featured photo by PublicDomainPictures on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

July 09, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

Delivra Health CEO Gord Davey discusses Middle East expansion with new Dubai UAE sales territory

Delivra Health Brands Inc.

Delivra Health Brands Inc. (TSX-V:DHB) CEO Gord Davey discusses the company’s recent expansion efforts in the Middle East during an interview with Proactive's Stephen Gunnion. Davey highlighted a successful trip to Dubai, where Delivra has partnered to target the United Arab Emirates (UAE) as a new sales territory. This move aligns with the company's strategy to expand its brand presence in the region. Delivra's product, Dream Water, which is already registered as a drug product and widely available in pharmacies across Saudi Arabia, will now be distributed throughout the UAE. Davey acknowledged the challenges faced during the nine-month process of regulatory approvals but credited their local partner’s expertise in navigating these complexities. He emphasized the significant market potential in the UAE, driven by a growing population and widespread sleep issues, which Dream Water aims to address. Looking ahead, Davey mentioned ongoing efforts to expand into additional territories in the Middle East, although he did not specify which countries due to pending regulatory approvals. He assured that the company is committed to global growth and will continue to update shareholders on progress. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

July 04, 2024 11:01 AM Eastern Daylight Time

Video
Article thumbnail News Release

This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment

Benzinga

By Johnny Rice, Benzinga Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), were recently guests on Benzinga’s All Access. Cingulate is a biotechnology company developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, relieving the pill burden many people with chronic conditions suffer. Cingulate was just given clearance by the FDA to seek full approval for its lead candidate, CTx-1301. Watch the full interview here: Featured photo by Hal Gatewood on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

July 03, 2024 08:30 AM Eastern Daylight Time

Video Image
Article thumbnail News Release

Vivos One Step Closer To Transforming Cancer Treatment With FDA Application To Start Human Trials For Pioneering Injectable Brachytherapy Device

Vivos Inc.

By Meg Flippin, Benzinga In what could prove to be a transformational development in cancer treatment, Vivos (OTCQB: RDGL), the maker of the Radiogel™ Precision Radionuclide Therapy, submitted an application to the U.S. Food and Drug Administration (FDA) to initiate human clinical trials. The Investigational Device Exemption (IDE) application is an amendment addressing the FDA’s comments about the company’s previous application. Once it's granted approval, Vivos can begin testing its therapy on humans to treat solid metastatic tumors, particularly in lymph nodes associated with papillary thyroid cancer. How RadioGel Works RadioGel, a pioneering Yttrium-90-based injectable brachytherapy device, represents what the company says is a groundbreaking approach to cancer treatment. It is designed for patients who are either not eligible for surgery or have chosen not to undergo the procedure, particularly those with non-radioiodine avid disease and limited burden regional nodal disease. The therapy involves directly injecting a hydrogel containing Yttrium-90 phosphate microparticles into the tumor. This method allows for a more localized and potent radiation treatment compared to traditional external-beam radiation therapies. First Filing Since Breakthrough Device Designation The application marks Vivos’ first filing with the FDA since being granted FDA Breakthrough Device Designation for the Radiogel ™ Precision Radionuclide Therapy. The Breakthrough Devices Program by the FDA is designed to accelerate the development and review of innovative technologies that show potential for more effective treatment options. The program's support is instrumental in hastening patient access to promising medical advancements like RadioGel. The technology behind RadioGel allows for the safe delivery of higher doses necessary for treating non-resectable and radiation-resistant cancers. The product also boasts a short half-life, delivering over 90% of its therapeutic radiation within ten days. That will be welcome news to cancer sufferers, given other treatments can require up to six weeks for a full course of radiation therapy. Additionally, the outpatient nature of the RadioGel therapy means patients can return home without concerns about radiation exposure to family members. Vivos Is Ready Since receiving that status, Vivos said the communication with the FDA has improved further, which is important to ushering this treatment along. The IDE filing includes reports on two studies – RadioGel genotoxicity and the retention of RadioGel at the injection site in VX2 tumors in rabbits. Vivos said the IDE submission addressed the 63 FDA comments received in previous FDA correspondences. In some cases, the company repeated underlying testing to strengthen its answers with current data. “We are mindful that most of the twelve FDA reviewers have joined in the past two years and we anticipate they will have some comments after reviewing the extensive material in our filing, which we are prepared to address promptly,” said Dr. Michael Korenko, President and CEO of Vivos. “We are eager to secure the FDA’s IDE approval so that we can submit our plan to the Mayo Clinic's Independent Review Board (IRB) for clearance to initiate the first in human clinical trials. This is an exciting time for Vivos and we are committed to bringing a new treatment option to patients in the fight against challenging cancer types. Initially our collaboration with Mayo will be targeting solid metastatic tumors in lymph nodes associated with papillary thyroid cancer.” Vivos, in collaboration with the Mayo Clinic, is working hard to develop treatments to fight challenging cancer types, offering hope and potentially more effective treatment options to people around the globe. The IDE application puts it one step closer to realizing that dream. Featured photo by National Cancer Institute on Unsplash. Vivos Inc. has developed a Yttrium-90-based injectable Precision Radionuclide Therapy brachytherapy device to treat solid tumors in animals (IsoPet®) and humans (RadioGel™). Using the company's proprietary hydrogel technology, brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Michael K. Korenko info@vivosinc.com Company Website http://www.vivosincusa.com

July 02, 2024 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

AmeriLife Expands Wealth Distribution Portfolio with Acquisition of WerksGroup

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, announced today a strategic partnership with WerksGroup, LLC and its primary business line, MyFedRetirementWerks, helping Federal Employees optimize their retirement and benefit options. This partnership will enhance the retirement and life insurance guidance available to federal employees, offering a more comprehensive range of solutions to help them achieve their long-term financial goals. Per the agreement, the terms of the deal were not disclosed. “Our company began with a simple phrase: ‘One big purpose,’” said Richard and Karen Wolfe, principals of WerksGroup, LLC. “We believe that financial guidance is more than just selling products. It is the pursuit of helping clients create and implement a plan to achieve their long-term life goals. Partnering with AmeriLife strengthens that mission, broadens our reach, and merges our core values seamlessly.” With over 60 years of combined retirement planning and life insurance expertise, WerksGroup, LLC has built its business on the idea that relationships are more important than sales. As such, the company has focused on nurturing a client base of those who serve the American people, including employees of the U.S. Postal Service, the Department of Veteran Affairs, the Central Intelligence Agency, and various other federal agencies and departments. “Our success and this partnership would not have been possible without the dedication of our management team and minority partners, Patrick Shehan from our sales division in the postal and federal market, and Mark Ross, who was critical in expanding our annuity market. Their contributions were exemplary in bringing our vision to fruition and building WerksGroup into a great organization,” added Richard and Karen. As part of AmeriLife Wealth Group, WerksGroup will gain access to a best-in-class platform that delivers efficiency, value, and access to diverse resources and services to increase their productivity and grow their bottom line. “We are immensely impressed with Richard and Karen and their dedication and expertise while growing WerksGroup,” said AmeriLife Chief Distribution Officer of Wealth Distribution Mike Vietri. “Their exceptional work in the life insurance and annuity sectors has played a pivotal role in ensuring the retirement comfort of their federal employee clients. We are excited to integrate their strengths into our portfolio and continue building on their success.” About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For over 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers through a distribution network of over 300,000 insurance agents, financial professionals, and over 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com and follow AmeriLife on Facebook and LinkedIn. About WerksGroup, LLC Founded on a simple yet profound principle, WerksGroup, LLC is committed to assisting clients nationwide in preparing for their immediate needs and future aspirations. With over 60 years of combined expertise in retirement and life insurance, our team understands that trustworthy financial guidance involves more than just offering products—it requires a deep, comprehensive understanding of each client's financial, familial, and estate planning goals. Contact Details Media Inquiries Jeff Maldonado media@amerilife.com Partnership Inquiries Patrick Nichols corporatedevelopment@amerilife.com Company Website https://amerilife.com/

July 01, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Shedding Light on Cystic Fibrosis

YourUpdateTV

Cystic fibrosis (CF) is a rare, progressive, and genetic disease that currently affects about 40,000 people in the United States. CF is the result of a defective gene, inherited from each parent, and the disease can impact people of all races and ethnicities. Recently, KC White, Board Chair of the Cystic Fibrosis Foundation, participated in a nationwide satellite media tour to discuss the disease, her personal journey, and how the Foundation is helping progress care and treatment options. A video accompanying this announcement is available at: https://youtu.be/8wj8u0JEqLU CF is a life-shortening disease that prevents our bodies from clearing mucus. This can lead to lung infections, poor nutrition, lung disease, and a host of unique challenges that can impact every aspect of a person’s life. When it was first discovered, it was considered a fatal pediatric disease. But due to transformative advancements in treatments and high-quality care, the life-expectancy for someone born with CF today is 56. While that number is climbing there is still a long way to go and unfortunately, not all people with CF equally benefit from this progress. KC White was elected chair of the Cystic Fibrosis Foundation’s Board of Trustees in 2022 after serving on the Board since 2005. Diagnosed with cystic fibrosis at age 3, White has been a committed volunteer and inspiring advocate for the Foundation since childhood and is the first person with CF to serve as board chair. When she was diagnosed, she wasn’t expected to live past high school age, but her family refused to accept that fate, which prompted their dedication to the Foundation’s work. Because of recent treatments known as modulators, about 90% of the CF population (including KC) experienced an incredible transformation in their health. With this though, comes navigating unplanned challenges including careers, finances, family, and more. In addition to fueling the research, particularly in genetic therapies, that will lead to transformative treatments for the entire CF population, the CF Foundation works to support the CF community in all aspects of their lives through support programs and fostering connection opportunities. The CF Foundation is committed to finding a cure and providing all people with CF the opportunity to lead long, fulfilling lives. The Foundation is aggressively funding research and drug development, advancing high-quality, specialized care, and partnering with and advocating for the CF community. For more information, visit CFF.ORG About KC White KC White was elected chair of the Cystic Fibrosis Foundation’s Board of Trustees in 2022 after serving on the Board since 2005. Diagnosed with cystic fibrosis at age 3, White has been a committed volunteer and inspiring advocate for the Foundation since childhood, speaking at her first Foundation event when she was only 9 years old. She is the first person with CF to serve as board chair. White received her Master of Applied Positive Psychology from the University of Pennsylvania in 2022 and currently serves as an assistant instructor in the program. She is also the Head Varsity Women’s Lacrosse coach for the Chagrin Falls, Ohio, Tigers. She and her husband, Justin, have one son, Mac. About the Cystic Fibrosis Foundation The Cystic Fibrosis Foundation is a donor-supported nonprofit organization leading the relentless pursuit of a cure for cystic fibrosis. The Foundation is committed to providing all people with CF the opportunity to lead long, fulfilling lives by funding research and drug development, advancing high-quality, specialized care, and partnering with and advocating for the CF community. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. The organization supports and accredits a national network of over 130 CF care centers recognized by the National Institutes of Health as a model of care for a chronic disease. Also, the Foundation manages support programs and fosters connection opportunities for the CF community. Based in Bethesda, Md., the Foundation’s impact is made possible by the work of nearly 70 local chapters across the country. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 28, 2024 12:45 PM Eastern Daylight Time

Video
Article thumbnail News Release

Tiziana Life Sciences adds to treasury with $3.4 million in non-dilutive funding

Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd (NASDAQ:TLSA) chairman and CEO Gabriele Cerrone joined Proactive's Stephen Gunnion with more details of the company's recent advancements and news. Tiziana Life Sciences is developing a fully human CD3 monoclonal antibody, delivered intranasally, specifically targeting neurodegenerative diseases such as multiple sclerosis (MS) and Alzheimer's disease. Cerrone discussed the company's progress in MS treatments, highlighting its expanded access trial at Harvard University's Brigham and Women's Hospital. Notably, 70% of patients in the trial showed improvement in fatigue scores, while 80% experienced reduced brain inflammation. The company is also preparing to dose the first Alzheimer's patients in a new trial approved by the FDA. Furthermore, Tiziana Life Sciences is exploring the combination of its drug with GLP-1 antagonists to target obesity-related diseases. Cerrone shared the exciting news of securing $3.4 million in non-dilutive funding, emphasising its commitment to protecting shareholder investments. "We have seen extraordinary improvements in patients, and we are thrilled about the potential impact of our treatments on neurodegenerative diseases," he remarked. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

June 28, 2024 07:53 AM Eastern Daylight Time

Video
12345 ... 267